Because estrogen receptor-positive (ER+) breast cancers account for approximately 70% of all breast malignancies, the estrobolome is of considerable interest for its capacity to modulate systemic estrogen levels and thus affect cancer risk and progression. This evidence concerns the gene ESR1 and cancer.